OVERVIEW

Paradigm Shifts in Migraine Treatment: Implications for Pharmacists is organized by Power-Pak C.E. - Continuing Education for Pharmacists & Pharmacy Technicians and will be held from Nov 01, 2018 - Nov 01, 2019.

Credits: 2.0 hours (0.20 CEU)

Target Audience:
This accredited activity has been designed for pharmacists.

Goal:
After completing this activity, pharmacists will have learned how CDK4/6 inhibitors positively affect HR+, HER-negative breast cancer care. Pharmacists will be able to offer expert advice on administration, drug interactions, and adverse effect management.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Describe unmet patient needs for migraine prevention.
• Effectively communicate the potential roles of CGRP in migraine pathophysiology.
• Discuss the use of receptor antagonists and monoclonal antibodies (mAbs) to block CGRP activity.
• Describe safety and efficacy data of anti-CGRP mAb compounds.
• Explain the landscape of new and emerging therapies for migraine prevention, including anti-CGRP mAbs.

Additional details will be posted as soon as they are available.